Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CHILDREN S ZYRTEC HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CHILDREN S ZYRTEC HIVES.
BROMPHENIRAMINE MALEATE vs CHILDREN'S ZYRTEC HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors, inhibiting histamine-mediated allergic reactions.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
5 mg or 10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life is approximately 8-11 hours in healthy adults, allowing twice-daily dosing.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Cetirizine is primarily excreted renally (~60% unchanged), with ~10% fecal excretion.
Category C
Category C
Antihistamine
Antihistamine